Stocks · News reference
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co raised the price target for argenx SE - ADR (NASDAQ: ARGX) from $940 to $1,202. Goldman Sachs boosted PBF Energy Inc (NYSE: PBF) price target from $71 to $81. B of A Securities increased price target for Americold Realty Trust Inc (NYSE: COLD) from $15 to $16.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.
Crypto-linked equities ripped higher as Bitcoin cleared $80,000, but the S&P 500 slipped with the 10-year Treasury yield back above 5%.
The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.
The global immunotherapy drugs market is experiencing significant growth driven by advances in biotechnology, rising demand for targeted treatments, and expanding therapeutic applications across cancer, autoimmune, and inflammatory diseases. Key growth factors include increasing disease burden, robust drug pipelines, personalized medicine adoption, and combination therapy development. The Americas and Europe remain dominant markets, while Asia-Pacific is emerging as a high-growth region. Major pharmaceutical and biotech companies are increasing R&D investments and collaboration to accelerate innovation.
Filed: 2026-09-10 AccNo: 0001628280-26-061392 Size: 147 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers